Plasma VEGF-related polymorphisms are implied in autoimmune thyroid diseases

Abstract Autoimmune thyroid diseases (AITD), including Graves’ disease (GD) and Hashimoto thyroiditis (HT), are complex multifactorial diseases. Vascular endothelial growth factor (VEGF) is implicated in various inflammatory diseases, especially autoimmune diseases. Our aim was to elucidate the relationships between plasma VEGF levels and four genome-wide association study-identified single nucleotide polymorphisms (SNPs) related to VEGF with AITD in Tunisian patients. A total of 364 healthy controls and 389 patients with AITD were genotyped for the SNPs rs6921438, rs4416670, rs6993770 and rs10738760. Levels of thyroid hormones and antibodies were quantified simultaneously with plasma VEGF after a period of six months of treatment. We found that the minor alleles of rs10738760 and rs6921438 are associated with the presence of GD. A allele of rs10738760 polymorphism is associated with increased plasma levels of free tri-iodothyronin (FT3) while no relationship was found with circulating VEGF plasma levels after six months of treatment. We also showed that the T allele of rs4416670 polymorphism was associated with increased risk of hyperthyroidism in patients treated for six months, independently of their initial diagnosis. There was no significant association between the SNPs and the risk for HT compared with controls. This study shows that AITD are influenced by 3 SNPs linked to VEGF circulating levels. Whereas rs10738760 appeared specific to GD and FT3 production after six months of treatment, rs6921438 and rs4416670 were implicated in the risk for GD. This study opens new ways to test pharmacogenomics concepts in the future especially in GD in which recurrence prognosis is still challenging.

[1]  Ashutosh Kumar Singh,et al.  Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. , 2015, Blood.

[2]  M. Niedziela,et al.  The clinical role of serum concentrations of selected cytokines: IL-1β, TNF-α and IL-6 in diagnosis of autoimmune thyroid disease (AITD) in children , 2014, Autoimmunity.

[3]  S. Mousa,et al.  Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis , 2014, OncoTargets and therapy.

[4]  M. Niedziela,et al.  The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). , 2014, Endokrynologia Polska.

[5]  F. B. Davis,et al.  Nuclear monomeric integrin αv in cancer cells is a coactivator regulated by thyroid hormone , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  Jinhui You,et al.  [Measurement and correlation analysis of plasma VEGF level in the patients of hyperthyroidism]. , 2013, Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi.

[7]  S. Doǧru-Abbasoǧlu,et al.  Vascular endothelial growth factor polymorphisms increase the risk of developing Graves' disease. , 2012, International immunopharmacology.

[8]  Terry J. Smith,et al.  Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy. , 2012, Best practice & research. Clinical endocrinology & metabolism.

[9]  R. Vasan,et al.  Identification of cis- and trans-Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels , 2011, Circulation research.

[10]  I. Brandslund,et al.  The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. , 2010, Gynecologic oncology.

[11]  F. B. Davis,et al.  L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. , 2009, American journal of physiology. Cell physiology.

[12]  F. Sánchez‐Madrid,et al.  Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features. , 2009, The Journal of clinical endocrinology and metabolism.

[13]  A. Hamzaoui,et al.  Vascular endothelial growth factor gene polymorphisms and serum levels in Behçet's disease. , 2008, Tissue antigens.

[14]  P. Korošec,et al.  Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy , 2008, Molecular vision.

[15]  Megan J. Hora,et al.  Effects of thyroidectomy, T4, and DITPA replacement on brain blood vessel density in adult rats. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[16]  P. Kraft,et al.  Genotypes and haplotypes of the VEGF gene are associated with higher mortality and lower VEGF plasma levels in patients with ARDS , 2007, Thorax.

[17]  Y. Shoenfeld,et al.  Vascular Endothelial Growth Factor (VEGF) in Autoimmune Diseases , 2007, Journal of Clinical Immunology.

[18]  P. Rutgeerts,et al.  The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease , 2006, Inflammatory bowel diseases.

[19]  L. Nisticò,et al.  Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis , 2006, Experimental dermatology.

[20]  J. Alexander,et al.  VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[21]  N. Bresolin,et al.  VEGF gene variability and type 1 diabetes: evidence for a protective role , 2006, Immunogenetics.

[22]  L. Moeller,et al.  Cytosolic action of thyroid hormone leads to induction of hypoxia-inducible factor-1alpha and glycolytic genes. , 2005, Molecular endocrinology.

[23]  Hung-Yun Lin,et al.  Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. , 2005, Endocrinology.

[24]  B. Goichot,et al.  Antithyroid drugs , 2005, The New England journal of medicine.

[25]  A. Weetman.  Cellular immune responses in autoimmune thyroid disease , 2004, Clinical endocrinology.

[26]  B. Brüne,et al.  Thyroid hormone induces erythropoietin gene expression through augmented accumulation of hypoxia-inducible factor-1. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[27]  L. Debusk,et al.  Dual functional roles of Tie-2/angiopoietin in TNF-α-mediated angiogenesis , 2004 .

[28]  L. Debusk,et al.  Dual functional roles of Tie-2/angiopoietin in TNF-alpha-mediated angiogenesis. , 2004, American journal of physiology. Heart and circulatory physiology.

[29]  P.F. Jones,et al.  Not just angiogenesis—wider roles for the angiopoietins , 2003, Journal of Pathology.

[30]  D. Ray,et al.  Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. , 2003, Cancer research.

[31]  Wei Zheng,et al.  DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth. , 2003, American journal of physiology. Heart and circulatory physiology.

[32]  M. Shibuya,et al.  Expression of vascular endothelial growth factor (VEGF) and VEGF receptor-1 (Flt-1) in Graves disease possibly correlated with increased vascular density. , 2001, Human pathology.

[33]  W. Renner,et al.  A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels , 2000, Journal of Vascular Research.

[34]  J. Ramsden,et al.  Angiogenesis in the thyroid gland. , 2000, The Journal of endocrinology.

[35]  D. Robie,et al.  The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. , 2000, Thyroid : official journal of the American Thyroid Association.

[36]  M. Shibuya,et al.  Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. , 1999, Human pathology.

[37]  M. Iitaka,et al.  Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. , 1998, The Journal of clinical endocrinology and metabolism.

[38]  G. Viglietto,et al.  Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization , 1997, Oncogene.

[39]  A. Mantovani,et al.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.

[40]  K. Yamazaki,et al.  Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. , 1995, The Journal of clinical investigation.

[41]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. , 1995, International archives of allergy and immunology.

[42]  H. Dvorak,et al.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. , 1992, Molecular biology of the cell.

[43]  M. Marcus,et al.  Thyroxine-induced left ventricular hypertrophy in the rat. Anatomical and physiological evidence for angiogenesis. , 1985, Circulation research.

[44]  L. Ericson,et al.  Blood capillary enlargement during the development of thyroid hyperplasia in the rat. , 1978, Endocrinology.